reports
- David Nierengarten
- Dennis Pak
- Martin Fan
- Wedbush Research
MU MICRON TECHNOLOGY INC.
MCS MARCUS CORPORATION
INTC INTEL CORPORATION
IMAX IMAX CORPORATION
GOOGL ALPHABET INC. CLASS A
FB FACEBOOK INC. CLASS A
CNK CINEMARK HOLDINGS INC.
AMC AMC ENTERTAINMENT HOLDINGS INC. CLASS A
NFLX NETFLIX INC.
EGHT 8X8 INC.
PTGX PROTAGONIST THERAPEUTICS
ROKU ROKU INC. CLASS A
AMZN AMAZON.COM INC.
AAPL APPLE INC.
NICE NICE LTD
DOCU DOCUSIGN INC.
LYFT LYFT
PINS PINTEREST INC. CLASS A
UBER UBER TECHNOLOGIES INC.
ORIC ORIC PHARMACEUTICALS
PRAX PRAXIS PRECISION MEDICINES
XOS XOS INC.
ALIT FOLEY TRASIMENE ACQUISITION CORP
TTD THE TRADE DESK
GMTX INC.
NUVL GEMINI THERAPEUTICS INC
CART NUVALENT INC
BCAX MAPLEBEAR INC.
BICARA THERAPEUTICS INC.
- Yun Zhong
Rusfertide Ph3 And Ph2 Long-Term Data At ASH Show Strong Durability
Figure 1 - Rapid Response from Rusfertide TreatmentSource: Company data; Wedbush researchFigure 2 - Ph3 52-Week Data Show Durable Response from Rusfertide TreatmentSource: Company dataFigure 3 - Design of the REVIVE and THRIVE StudiesSource: Company data; Wedbush researchFigure 4 - Long-Term Rusfer
- David Nierengarten
- Dennis Pak
- Martin Fan
- David Nierengarten
- Dennis Pak
- Geoffrey Von Der Ahe
- Laura Chico
- Martin Fan
- Ritika Das
- Robert Driscoll
- Thomas Yip
- Yun Zhong
KURA KURA ONCOLOGY INC.
FATE FATE THERAPEUTICS INC
WVE WAVE LIFE SCIENCES
PTGX PROTAGONIST THERAPEUTICS
ORIC ORIC PHARMACEUTICALS
BEAM BEAM THERAPEUTICS
RZLT REZOLUTE
CGEM CULLINAN ONCOLOGY INC
TCRX TSCAN THERAPEUTICS INC
GMTX GEMINI THERAPEUTICS INC
BCAX BICARA THERAPEUTICS INC.
- Wedbush Research
WDC WESTERN DIGITAL CORPORATION
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
MU MICRON TECHNOLOGY INC.
INTC INTEL CORPORATION
GOOGL ALPHABET INC. CLASS A
FB FACEBOOK INC. CLASS A
FATE FATE THERAPEUTICS INC
BIIB BIOGEN INC.
BCRX BIOCRYST PHARMACEUTICALS INC.
AXTI AXT INC.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
PTGX PROTAGONIST THERAPEUTICS
ANAB ANAPTYSBIO INC.
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
STOK STOKE THERAPEUTICS
SMCI SUPER MICRO COMPUTER
ACET INC.
STTK ADICET BIO INC
TVTX SHATTUCK LABS
VRDN TRAVERE THERAPEUTICS INC
SANA VIRIDIAN THERAPEUTICS INC
PHVS SANA BIOTECHNOLOGY
DAWN PHARVARIS NV
STX DAY ONE BIOPHARMACEUTICALS INC
GFS SEAGATE TECHNOLOGY HLDGS PLC
EWTX GLOBALFOUNDRIES INC
NUVL EDGEWISE THERAPEUTICS INC
ARTV NUVALENT INC
SYRE ARTIVA BIOTHERAPEUTICS INC
RNAC SPYRE THERAPEUTICS INC.
CARTESIAN THERAPEUTICS INC
- David Nierengarten
- Dennis Pak
- Geoffrey Von Der Ahe
- Martin Fan
- Ritika Das
- Robert Driscoll
- Yun Zhong
- Wedbush Research
TTWO TAKE-TWO INTERACTIVE SOFTWARE INC.
TSLA TESLA INC
TRIP TRIPADVISOR INC.
EXPE EXPEDIA GROUP INC.
CTMX CYTOMX THERAPEUTICS INC.
BCRX BIOCRYST PHARMACEUTICALS INC.
NFLX NETFLIX INC.
INOD INNODATA
PTGX PROTAGONIST THERAPEUTICS
NTLA INTELLIA THERAPEUTICS INC.
ANAB ANAPTYSBIO INC.
ROKU ROKU INC. CLASS A
RCKT ROCKET PHARMACEUTICALS
BKNG BOOKING HOLDINGS INC.
DNLI DENALI THERAPEUTICS INC
HEAR TURTLE BEACH CORP.
STRO SUTRO BIOPHARMA
STTK SHATTUCK LABS
ABNB AIRBNB INC. CLASS A
IMNM IMMUNOME
SANA SANA BIOTECHNOLOGY
PLTK PLAYTIKA HOLDING
TTD THE TRADE DESK
GLUE INC.
ATXS MONTE ROSA THERAPEUTICS INC
JANX ASTRIA THERAPEUTICS INC
YOU JANUX THERAPEUTICS INC
SOUN CLEAR SECURE INC
EWTX SOUNDHOUND AI INC
SYRE EDGEWISE THERAPEUTICS INC
NATL SPYRE THERAPEUTICS INC.
OS NCR ATLEOS CORPORATION
MAZE ONESTREAM INC
CBIO MAZE THERAPEUTICS INC
SNDK CRESCENT BIOPHARMA INC.
SANDISK CORP
- Yun Zhong
- Wedbush Research
MCS MARCUS CORPORATION
LGIH LGI HOMES INC.
IMAX IMAX CORPORATION
CNK CINEMARK HOLDINGS INC.
BMRN BIOMARIN PHARMACEUTICAL INC.
AMC AMC ENTERTAINMENT HOLDINGS INC. CLASS A
NFLX NETFLIX INC.
OSTK OVERSTOCK.COM INC.
DHI D.R. HORTON INC.
7974 NINTENDO CO. LTD.
PTGX PROTAGONIST THERAPEUTICS
DBD DIEBOLD NIXDORF INCORPORATED
- Yun Zhong
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
UEC URANIUM ENERGY CORP
NEO NEOGENOMICS INC.
MO ALTRIA GROUP INC
HNRG HALLADOR ENERGY CO.
CODI COMPASS DIVERSIFIED HOLDINGS
CBOE CBOE GLOBAL MARKETS INC
ABC AMERISOURCEBERGEN CORPORATION
KO COCA-COLA COMPANY
PTGX PROTAGONIST THERAPEUTICS
UAMY UNITED STATES ANTIMONY CORP.
COKE COCA-COLA CONSOLIDATED INC.
RVMD REVOLUTION MEDICINES
PCVX VAXCYTE
NVTS NAVITAS SEMICONDUCTOR CORP
GLUE MONTE ROSA THERAPEUTICS INC
AIRS AIRSCULPT TECHNOLOGIES INC
JANX JANUX THERAPEUTICS INC
NAMS NEWAMSTERDAM PHARMA COMPANY B.V.
ATLX ATLAS LITHIUM CORPORATION
ZYME ZYMEWORKS INC.
NB NIOCORP DEVELOPMENTS LTD.
METC RAMACO RESOURCES INC.
BNTC BENITEC BIOPHARMA INC
CDTX CIDARA THERAPEUTICS INC.
ABAT AMERICAN BATTERY TECHNOLOGY COMPANY
ONEG ONECONSTRUCTION GROUP LIMITED
SION SIONNA THERAPEUTICS INC
- Yun Zhong
INVITE: Wedbush Analyst Call On PTGX & JNJ Situation Overview
We do not find the reported M&A discussion between JNJ and PTGX to be surprising given the existing collaboration on icotrokinra, which after potential FDA and EMA approvals in 2026 for PsO and with ongoing Ph3 programs for both IBD and PsA should target an over $5B market based on JNJ manageme
- Yun Zhong
Acquisition By JNJ Makes Sense But Valuation Is The Question
JNJ Only Needs to Pay at Most 10% Royalties on Icotrokinra to PTGX. Icotrokinra is included in a worldwide license and collaboration agreement that PTGX and JNJ initially entered into in May. '17 to co-develop and co-commercialize IL-23R antagonist compounds for various indications. A major milesto
- Wedbush Research
WDC WESTERN DIGITAL CORPORATION
TSLA TESLA INC
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
MU MICRON TECHNOLOGY INC.
INTC INTEL CORPORATION
AXTI AXT INC.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
PTGX PROTAGONIST THERAPEUTICS
ANAB ANAPTYSBIO INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
STTK SHATTUCK LABS
STX SEAGATE TECHNOLOGY HLDGS PLC
GFS GLOBALFOUNDRIES INC
SYRE SPYRE THERAPEUTICS INC.
DBD DIEBOLD NIXDORF INCORPORATED
- David Nierengarten
- Dennis Pak
- Martin Fan
- Yun Zhong
- Yun Zhong
KOL Comments Continue To Support Icotrokinra's Strong Potential In IBD
Icotrokinra Demonstrated a Clear Dose Response, across all efficacy endpoints except symptomatic remission (stool frequency subscore of 0 or 1 and rectal bleeding of 0), which showed continued improvement in all cohorts from treatment initiation through week 12. Additionally, the safety profile is
- Wedbush Research
TSLA TESLA INC
GOOGL ALPHABET INC. CLASS A
FB FACEBOOK INC. CLASS A
NFLX NETFLIX INC.
WVE WAVE LIFE SCIENCES
PTGX PROTAGONIST THERAPEUTICS
ANAB ANAPTYSBIO INC.
ROKU ROKU INC. CLASS A
MDB MONGODB INC. CLASS A
AMZN AMAZON.COM INC.
MSFT MICROSOFT CORPORATION
ACET ADICET BIO INC
STTK SHATTUCK LABS
BEAM BEAM THERAPEUTICS
PLTR PALANTIR TECHNOLOGIES
SNOW SNOWFLAKE INC. CLASS A
TTD THE TRADE DESK
PRME INC.
SYRE PRIME MEDICINE INC
JBIO SPYRE THERAPEUTICS INC.
JADE BIOSCIENCES INC
- David Nierengarten
- Dennis Pak
- Martin Fan
- Yun Zhong
- Wedbush Research
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.